Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2021 Jan 7:2021.01.07.425740.
doi: 10.1101/2021.01.07.425740.

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xuping Xie  1 , Jing Zou  1 , Camila R Fontes-Garfias  1 , Hongjie Xia  1 , Kena A Swanson  2 , Mark Cutler  2 , David Cooper  2 , Vineet D Menachery  3   4 , Scott Weaver  3   4 , Philip R Dormitzer  2 , Pei-Yong Shi  1   4   5   6   7
Affiliations

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xuping Xie et al. bioRxiv. .

Update in

Abstract

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.

PubMed Disclaimer

Conflict of interest statement

Competing financial interests

X.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system. K.A.S., M.C., D.C., and P.R.D. are employees of Pfizer and may hold stock options. X.P., J.Z., C.R.F.G., H.X., and P.-Y.S. received compensation from Pfizer to perform the neutralization assay.

Figures

Figure 1.
Figure 1.. 50% plaque reduction neutralization titers of 20 sera from BNT162b2 vaccine recipients against N501 and Y501 SARS-CoV-2.
Seven sera (indicated by triangles) were drawn 2 weeks after the second dose of vaccine; 13 sera (indicated by circles) were drawn 4 weeks after the second dose.
See this image and copyright information in PMC

References

    1. Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng. J Med 2020. DOI: 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Volz E, Mishra S, Chand M et al. Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-....
    1. Tegally H, Wilkinson E, Giovanetti M et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Afric. medRxiv 2020. 10.1101/2020.12.21.20248640 - DOI
    1. Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 2020;369:1603–7. - PMC - PubMed

Publication types

LinkOut - more resources